Showing results (641-650 of 1,005) with videos related to
Sort By:
Pageof 101
Journal of Neuroscience Research|June 7, 2007
Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discoveryMahalakshmi Shankaran, Michael E Marino, Robert Busch, et al.Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|May 31, 2007
A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgeryPierre Vereecken, Ahmad Awada, Ghanem Ghanem, et al.Cancer Chemotherapy and Pharmacology|August 21, 2015
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumoursB Venugopal, A Awada, T R J Evans, et al.Journal of Environmental Quality|December 10, 2020
Soil properties limiting vegetation establishment along roadsidesShad D Mills, Martha Mamo, Sabrina J Ruis, et al.Expert Opinion on Biological Therapy|May 27, 2021
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeuticsKamal S Saini, Kevin Punie, Chris Twelves, et al.Journal of Environmental Quality|October 27, 2023
Cover crop performance under a changing climate in continuous corn system over NebraskaGirma Birru, Andualem Shiferaw, Tsegaye Tadesse, et al.European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumoursPatrick Schöffski, Ahmad Awada, Herlinde Dumez, et al.Journal of the Neurological Sciences|October 31, 2000
A novel deletion mutation within the carboxyl terminus of the copper-transporting ATPase gene causes Wilson diseaseR Majumdar, M Al Jumah, S Al Rajeh, et al.Neurosciences (Riyadh, Saudi Arabia)|August 28, 2013
Diabetic neuropathy. Correlation with other diabetic microvascular complicationsSami A Bashi, Salem D Alsuwaidan, Adnan A Awada, et al.Anti-Cancer Drugs|January 23, 2016
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumorsAhmad Awada, Mario Campone, Andrea Varga, et al.Pageof 101